Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Roxadustat Market Grown from 2024 to 2025?
The market for Roxadustat has seen significant enlargement in past few years. It is projected to expand from a valuation of $6.44 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The historic period’s growth can be linked to numerous factors which includes obtaining regulatory consent in crucial markets, solid outcomes from clinical trials, the rise in cases of chronic kidney disease, increasing enlightenment about anemia management, and governmental backing for anemia therapies.
What Growth Rate Is Anticipated for the Roxadustat Market in the Coming Years?
Predictions suggest a striking growth in the Roxadustat market size over the next few years, expanding to $9.16 billion in 2029 with a compound annual growth rate (CAGR) of 7.3%. Several factors contributing to this growth during the prediction period include continuous exploration for discovering new indicators, escalating expenditure in healthcare, increased preference for non-injectable cures for anemia, broadening reimbursement policies, and an uptick in elderly populations. Key trends expected during this forecasting timeline encompass a transition towards orally administered anemia treatments, increased rivalry from alternative treatment options, broadening of licensing contracts, surge in investments towards research on hypoxia-inducible factor and evolving focus on a more patient-oriented treatment methodology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp
Who Are the Leading Companies in the Roxadustat Market?
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.
What Are the Key Drivers of the Roxadustat Market?
The increase in individuals suffering from chronic kidney disease (CKD) is anticipated to stimulate the expansion of the Roxadustat market. Chronic kidney disease is a persistent ailment where the kidneys progressively lose their capacity to function adequately, frequently resulting in kidney failure if it’s not taken care of. Factors such as aging society, high diabetes prevalence, high blood pressure, and unhealthy lifestyles contribute to the escalating global count of chronic kidney disease cases. One of the ways Roxadustat contributes to managing CKD is by prompting the production of erythropoietin, which elevates the production of red blood cells and aids in correcting anemia, a common occurrence with this disease. This improves the overall functioning of the kidneys and the quality of life for patients. Taking a specific incident from December 2024 according to the Australian Institute of Health and Welfare (AIHW), a government agency in Australia, there was a mild yearly increase in the mortality rates due to chronic kidney disease, with a rise of 4.2% in 2021 and 6.2% in 2022. Hence, the escalating population of individuals with chronic kidney disease (CKD) is fueling the Roxadustat market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp
What Are the Key Market Segments in the Roxadustat Industry?
The roxadustat market covered in this report is segmented –
1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions
Subsegments:
1) By 20mg: Oral Tablets, Injectable Formulations
2) By 50mg: Oral Tablets, Injectable Formulations
What Are the Latest Trends in the Roxadustat Market?
Companies prominent in the Roxadustat marketplace are leveraging the high-tech drugs scheme for reimbursements, aiming to broaden their patient reach by minimizing financial obstacles. This move is boosting market adoption and showcasing the cost-efficiency of their pioneering treatments. The high-tech drugs scheme is predominantly government-controlled, primarily in Ireland, and allows for the payment-back of costly, highly specialized medications that are commonly dispensed in hospital environments. For example, in September 2022, Astellas Pharma Company Ltd., an American pharmaceutical firm, revealed that its EVRENZO (Roxadustat) received reimbursement via the High-Tech Drugs Scheme in Ireland. Roxadustat is the inaugural medication in a new category of orally consumed hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors that have been licensed and reimbursed in Ireland. The findings indicated that Roxadustat was successful in achieving and sustaining target hemoglobin levels (10-12g/dL) for patients suffering from symptomatic anemia of CKD, irrespective of their dialysis status and previous ESA treatment.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report
What Are the Key Regional Markets in the Roxadustat Industry?
North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280
This Report Delivers Insight On:
1. How big is the roxadustat market, and how is it changing globally?
2. Who are the major companies in the roxadustat market, and how are they performing?
3. What are the key opportunities and risks in the roxadustat market right now?
4. Which products or customer segments are growing the most in the roxadustat market?
5. What factors are helping or slowing down the growth of the roxadustat market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model